Natco Pharma announced the launch of Carboplatin Injection, a generic version of Paraplatin® in the U.S. market by its U.S. subsidiary NATCO Pharma USA LLC.

Natco has launched this product in manufacturing collaboration with Teyro Labs, based in Chennai.

This launch helps address a critical shortage of the product in the U.S. market. Carboplatin Injection is indicated for the treatment of advanced ovarian carcinoma, including first-line combination therapy and palliative treatment of recurrent disease after prior chemotherapy.

Carboplatin Injection had estimated sales of USD 27.8 million in the U.S. for 12 months ending June'26 as per industry sales data.